Alkem Laboratories Limited (NSE:ALKEM)

Elevation Oncology Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	3,041	4,551	2,738	2,322	1,742
Short-Term Investments	28,983	36,665	7,339	9,424	14,123
Trading Asset Securities	9,023	1,482	1,355	1,385	1,671
Cash & Short-Term Investments	41,047	42,697	11,432	13,130	17,537
Cash Growth	-3.86%	273.50%	-12.94%	-25.13%	281.00%
Accounts Receivable	25,076	22,855	21,442	18,880	16,072
Other Receivables	782.1	1,658	1,782	1,607	2,829
Receivables	25,949	24,603	23,292	20,689	19,088
Inventory	29,224	26,612	26,075	30,055	23,124
Prepaid Expenses	595.3	499.1	443.9	564.4	303.6
Other Current Assets	12,643	9,704	26,054	19,915	9,235
Total Current Assets	109,458	104,116	87,297	84,354	69,288
Property, Plant & Equipment	28,627	25,570	25,135	27,659	27,064
Long-Term Investments	12,988	4,051	5,249	8,803	1,586
Goodwill	4,231	4,167	4,132	4,031	3,954
Other Intangible Assets	1,146	575.8	793.9	721.9	844.4
Long-Term Deferred Tax Assets	17,383	15,148	13,025	13,093	11,079
Other Long-Term Assets	3,078	2,120	1,855	1,950	1,297
Total Assets	176,911	155,749	137,567	140,692	115,193
Accounts Payable	18,394	17,481	11,650	11,734	10,694
Accrued Expenses	5,073	4,889	9,248	7,941	6,443
Short-Term Debt	7,349	11,726	13,071	25,706	16,360
Current Portion of Long-Term Debt	169.9	13.4	0.3	1.2	368.3
Current Portion of Leases	506.9	151.8	192	216	215.5
Current Income Taxes Payable	611	549.9	234.4	163.2	189.3
Current Unearned Revenue	39	39.1	10.5	12.4	16.8
Other Current Liabilities	7,508	5,095	2,665	2,280	1,754
Total Current Liabilities	39,650	39,946	37,072	48,053	36,041
Long-Term Debt	3,109	400	-	93.8	279.3
Long-Term Leases	2,674	1,893	703.3	664.7	697.1
Long-Term Unearned Revenue	219.5	258.4	88	79.2	88.3
Other Long-Term Liabilities	4,765	4,178	3,652	1,775	1,311
Total Liabilities	52,575	48,605	43,217	52,219	39,613
Common Stock	239.1	239.1	239.1	239.1	239.1
Retained Earnings	119,603	102,970	90,392	85,811	73,540
Comprehensive Income & Other	7	-88	-178.4	328.5	-11.8
Total Common Equity	119,849	103,121	90,453	86,379	73,767
Minority Interest	4,488	4,023	3,897	2,094	1,813
Shareholders' Equity	124,336	107,144	94,350	88,473	75,580
Total Liabilities & Equity	176,911	155,749	137,567	140,692	115,193
Total Debt	13,809	14,184	13,967	26,682	17,920
Net Cash (Debt)	27,238	28,513	-2,535	-13,552	-382.8
Net Cash Growth	-4.47%	-	-	-	-
Net Cash Per Share	227.81	238.47	-21.20	-113.34	-3.20
Filing Date Shares Outstanding	119.57	119.57	119.57	119.57	119.57
Total Common Shares Outstanding	119.57	119.57	119.57	119.57	119.57
Working Capital	69,808	64,170	50,225	36,301	33,248
Book Value Per Share	1002.37	862.46	756.52	722.44	616.96
Tangible Book Value	114,472	98,377	85,527	81,626	68,969
Tangible Book Value Per Share	957.40	822.79	715.32	682.69	576.83
Land	1,245	1,365	1,369	1,373	2,014
Buildings	9,676	10,226	8,786	9,672	8,807
Machinery	24,848	23,690	21,710	22,554	19,732
Construction In Progress	4,766	1,484	3,103	3,395	3,933
Leasehold Improvements	250.1	107	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.